All arrangements will be made for providing vaccines to Haj pilgrims: Nadda

Image
Press Trust of India New Delhi
Last Updated : Apr 23 2019 | 3:55 PM IST

Union Health Minister J P Nadda has said all arrangements will be made for providing vaccines to Haj pilgrims, following reports of paucity of meningitis vaccines in the country as the only firm manufacturing it was asked to stop production last year after contamination was detected in its oral polio vaccines.

The minister reviewed the availability of vaccines with the health secretary and senior officials on Monday.

"I assure that all arrangements will be made for providing vaccines to the Haj pilgrims," Nadda said a tweet.

According to sources in the Health Ministry, the only firm, which manufactured the vaccines and provided it to the government, was asked to stop production of all human vaccines in September last year after type-2 polio virus contamination was detected in oral polio vaccines.

Following the ban on the Ghaziabad-based pharmaceutical company, Biomed Pvt. Ltd., the ministry is now looking for options to arrange the vaccines in time for vaccinating the pilgrims, the sources said.

Around 1.27 lakh people are expected to go for the annual Haj pilgrimage in July this year for which the ministry will have to arrange for at least 1.9 lakh doses.

Extra vaccines are kept as some are rendered ineffective in the process of delivery to the states.

The Health Ministry is already in talks with two firms which import the vaccines, the sources said.

Those going to Saudi Arabia for the purpose of 'Umrah' are required to submit a certificate of vaccination with the quadrivalent (ACYW 135) vaccine against meningitis, proving the vaccine was administered no more than three years ago and no less than 10 days before arrival in the country.

Biomed Pvt. Ltd. was a licensed indigenous manufacturer for Meningococcal Polysaccharide vaccine while two Mumbai-based firms M/s Sanofi Pastuer India Pvt. Lt. and M/s GlaxoSmithkline Pharmaceuticals Ltd. are importers for quadrivalent Meningcoccal Meningitis Conjugate Vaccine in the country.

"Earlier with Biomed Pvt. Ltd. providing the vaccines, government spent Rs 250 for each vaccine but now if they have to buy from companies which import the vaccines, they may have to shell out around Rs 1,500 per dose. The Health Ministry is already in talks with the two firms which import the vaccines," the sources said.

Biomed Pvt. Ltd. was directed to stop the manufacture, sale and distribution of all human vaccines, including the Quadrivalent Meningococcal Meningitis vaccine, after type-2 polio virus was found in the sewage and stool samples in Maharashtra, Telangana and Uttar Pradesh in September last year.

The polio drops were sent for testing which confirmed that some of them were contaminated with type-2 virus, a strain believed to have been eradicated in 2016.

The managing director of Biomed Pvt. Ltd., which was supplying polio vaccines for only government-run immunisation programmes, was arrested after the central drug regulator filed a complaint and an FIR was registered.

The destruction of traces of type-2 polio virus was ordered by the central drug regulator to all manufacturers in 2016.

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Apr 23 2019 | 3:55 PM IST

Next Story